ArticleJournal of neurology, neurosurgery, and psychiatry2023
Emerging role of vascular burden in AT(N) classification in individuals with Alzheimer's and concomitant cerebrovascular burdens.
Article in Journal of neurology, neurosurgery, and psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Multimodal Retinal Imaging for the Detection of Early Alzheimer's Disease: Combining Biochemical, Structural, and Vascular Biomarkers.Bioengineering (Basel, Switzerland) · 2026Article
- Female vulnerability to microvascular transport dysfunction emerges early across the Alzheimer's disease continuum.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Elevated plasma klotho levels attenuate Alzheimer's disease pathologies and cognitive decline in APOE ε4 carriers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Cardiovascular Risk as a Moderator of the Relationship Between Plasma Alzheimer Disease Biomarkers and Cognitive Status.Journal of the American Heart Association · 2026Article
- Integrative analysis of AT classification, plasma biomarkers, and cognitive trajectories across diverse dementia syndromes.Scientific reports · 2025Article
- Cognitive Age Delta as a Marker of Healthy and Pathological Cognitive Aging: The Role of Lifestyle, Cognitive Reserve, and Vascular Risk.Journal of clinical medicine · 2025Article
- Micro infarcts are associated with cognitive impairment in neurofibrillary tangle predominant decedents: evidence from the NACC autopsy cohort.Alzheimer's research & therapy · 2025Article
- Ante-mortem cognitive trajectories associated with Aβ and tau biomarker profiles in older adults with cerebrovascular disease: a longitudinal cohort study.Alzheimer's research & therapy · 2025Article
- NeuroFANN: identification of neuropathological subtypes in dementia with plasma proteins by using functionally annotated neural network.Briefings in bioinformatics · 2025Article
- Distinct Characteristics of Suspected Non-Alzheimer Pathophysiology in Relation to Cognitive Status and Cerebrovascular Burden.Clinical nuclear medicine · 2025Article
- Plasma proteomics for cognitive decline and dementia-A Southeast Asian cohort study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217.The journal of prevention of Alzheimer's disease · 2025Article
- Korea-Registries to Overcome Dementia and Accelerate Dementia Research (K-ROAD): A Cohort for Dementia Research and Ethnic-Specific Insights.Dementia and neurocognitive disorders · 2024Article
- Trigeminal involvement in MOG antibody-associated brainstem encephalitis: a distinct clinico-radiographic presentation.Acta neurologica Belgica · 2024Article
- The relationship between amyloid pathology, cerebral small vessel disease, glymphatic dysfunction, and cognition: a study based on Alzheimer's disease continuum participants.Alzheimer's research & therapy · 2024Article
- Effects of Vascular Risk Factors on the Association of Blood-Based Biomarkers with Alzheimer's Disease.Medical research archives · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAlzheimer's disease (AD) is characterised by amyloid-beta accumulation (A), tau aggregation (T) and neurodegeneration (N). Vascular (V) burden has been found concomitantly with AD pathology and has synergistic effects on cognitive decline with AD biomarkers. We determined whether cognitive trajectories of AT(N) categories differed according to vascular (V) burden.
methodsWe prospectively recruited 205 participants and classified them into groups based on the AT(N) system using neuroimaging markers. Abnormal V markers were identified based on the presence of severe white matter hyperintensities.
resultsIn A+ category, compared with the frequency of Alzheimer's pathological change category (A+T-), the frequency of AD category (A+T+) was significantly lower in V+ group (31.8%) than in V- group (64.4%) (p=0.004). Each AT(N) biomarker was predictive of cognitive decline in the V+ group as well as in the V- group (p<0.001). Additionally, the V+ group showed more severe cognitive trajectories than the V- group in the non-Alzheimer's pathological changes (A-T+, A-N+; p=0.002) and Alzheimer's pathological changes (p<0.001) categories.
conclusionThe distribution and longitudinal outcomes of AT(N) system differed according to vascular burdens, suggesting the importance of incorporating a V biomarker into the AT(N) system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.